QQQ   351.85 (+1.11%)
AAPL   179.62 (+1.34%)
MSFT   330.70 (+0.70%)
META   272.76 (+3.04%)
GOOGL   123.27 (+0.33%)
AMZN   123.16 (+2.14%)
TSLA   207.38 (+1.69%)
NVDA   398.71 (+5.38%)
NIO   7.63 (+1.33%)
BABA   83.64 (+5.14%)
AMD   120.11 (+1.61%)
T   15.78 (+0.32%)
F   12.12 (+1.00%)
MU   69.21 (+1.48%)
CGC   0.83 (-0.41%)
GE   104.95 (+3.37%)
DIS   88.60 (+0.73%)
AMC   4.62 (+2.67%)
PFE   37.98 (-0.11%)
PYPL   63.07 (+1.74%)
NFLX   405.01 (+2.47%)
QQQ   351.85 (+1.11%)
AAPL   179.62 (+1.34%)
MSFT   330.70 (+0.70%)
META   272.76 (+3.04%)
GOOGL   123.27 (+0.33%)
AMZN   123.16 (+2.14%)
TSLA   207.38 (+1.69%)
NVDA   398.71 (+5.38%)
NIO   7.63 (+1.33%)
BABA   83.64 (+5.14%)
AMD   120.11 (+1.61%)
T   15.78 (+0.32%)
F   12.12 (+1.00%)
MU   69.21 (+1.48%)
CGC   0.83 (-0.41%)
GE   104.95 (+3.37%)
DIS   88.60 (+0.73%)
AMC   4.62 (+2.67%)
PFE   37.98 (-0.11%)
PYPL   63.07 (+1.74%)
NFLX   405.01 (+2.47%)
QQQ   351.85 (+1.11%)
AAPL   179.62 (+1.34%)
MSFT   330.70 (+0.70%)
META   272.76 (+3.04%)
GOOGL   123.27 (+0.33%)
AMZN   123.16 (+2.14%)
TSLA   207.38 (+1.69%)
NVDA   398.71 (+5.38%)
NIO   7.63 (+1.33%)
BABA   83.64 (+5.14%)
AMD   120.11 (+1.61%)
T   15.78 (+0.32%)
F   12.12 (+1.00%)
MU   69.21 (+1.48%)
CGC   0.83 (-0.41%)
GE   104.95 (+3.37%)
DIS   88.60 (+0.73%)
AMC   4.62 (+2.67%)
PFE   37.98 (-0.11%)
PYPL   63.07 (+1.74%)
NFLX   405.01 (+2.47%)
QQQ   351.85 (+1.11%)
AAPL   179.62 (+1.34%)
MSFT   330.70 (+0.70%)
META   272.76 (+3.04%)
GOOGL   123.27 (+0.33%)
AMZN   123.16 (+2.14%)
TSLA   207.38 (+1.69%)
NVDA   398.71 (+5.38%)
NIO   7.63 (+1.33%)
BABA   83.64 (+5.14%)
AMD   120.11 (+1.61%)
T   15.78 (+0.32%)
F   12.12 (+1.00%)
MU   69.21 (+1.48%)
CGC   0.83 (-0.41%)
GE   104.95 (+3.37%)
DIS   88.60 (+0.73%)
AMC   4.62 (+2.67%)
PFE   37.98 (-0.11%)
PYPL   63.07 (+1.74%)
NFLX   405.01 (+2.47%)
NASDAQ:ORPN

Bioblast Pharma (ORPN) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$2.60
$2.63
50-Day Range
$11.50
$28.49
52-Week Range
$6.16
$30.00
Volume
26,876 shs
Average Volume
N/A
Market Capitalization
$1.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ORPN stock logo

About Bioblast Pharma (NASDAQ:ORPN) Stock

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.

Receive ORPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioblast Pharma and its competitors with MarketBeat's FREE daily newsletter.

ORPN Stock News Headlines

The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
Graphite versus Lithium - What Investors Should Know
Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.
ENLV Enlivex Therapeutics Ltd.
BioBlast up 64% on Trehalose deal with Seelos
See More Headlines


Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORPN
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.56 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.10 million
Optionable
Not Optionable
Beta
1.41

Key Executives

  • Oren Hershkovitz
    Chief Executive Officer
  • Shachar Shlosberger
    Chief Financial Officer
  • Dror Mevorach
    Chief Scientific & Medical Officer
  • Odelia Ben-Shitrit
    Head-Clinical Operations













ORPN Stock - Frequently Asked Questions

When did Bioblast Pharma's stock split?

Shares of Bioblast Pharma reverse split on the morning of Wednesday, March 6th 2019. The 1-8 reverse split was announced on Wednesday, March 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 5th 2019. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of Bioblast Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bioblast Pharma investors own include Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Verastem (VSTM), Voyager Therapeutics (VYGR), Athersys (ATHX), ContraFect (CFRX), CTI BioPharma (CTIC) and Eleven Biotherapeutics (EBIO).

What is Bioblast Pharma's stock symbol?

Bioblast Pharma trades on the NASDAQ under the ticker symbol "ORPN."

What is Bioblast Pharma's stock price today?

One share of ORPN stock can currently be purchased for approximately $2.62.

How much money does Bioblast Pharma make?

Bioblast Pharma (NASDAQ:ORPN) has a market capitalization of $1.10 million.

How can I contact Bioblast Pharma?

Bioblast Pharma's mailing address is PO Box 318, Tel-Aviv Is, 6100201. The official website for the company is bioblastpharma.com. The biopharmaceutical company can be reached via phone at (722) 670-8072 or via email at ir@bioblastpharma.com.

This page (NASDAQ:ORPN) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -